SCHEMBL5077331

SCHEMBL5077331

CN(C1c2ccccc2C=CC1N1CCCC1)S(=O)(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA3 P07451 1/20 0.40
CA4 P22748 1/20 0.40
CA6 P23280 1/20 0.40
CA5A P35218 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA13 Q8N1Q1 1/20 0.40
CA14 Q9ULX7 1/20 0.40
CA5B Q9Y2D0 1/20 0.40
ALDH1A1 P00352 5/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MCOLN3 Q8TDD5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4853119 1.00 SIGMAR1 (0.41) SIGMAR1CA12CA1CA2CA3
SCHEMBL4853113 1.00 SIGMAR1 (0.41) SIGMAR1CA12CA1CA2CA3
SCHEMBL7686316 0.91 SIGMAR1 (0.41) SIGMAR1CA12CA1CA2CA3
SCHEMBL4862048 0.91 SIGMAR1 (0.41) SIGMAR1CA12CA1CA2CA3
SCHEMBL4862058 0.91 SIGMAR1 (0.41) SIGMAR1CA12CA1CA2CA3
SCHEMBL4862260 0.88 SIGMAR1 (0.45) SIGMAR1CA12CA9ALDH1A1LMNA
SCHEMBL4862263 0.88 SIGMAR1 (0.45) SIGMAR1CA12CA9ALDH1A1LMNA
SCHEMBL5075203 0.88 SIGMAR1 (0.45) SIGMAR1CA12CA9ALDH1A1LMNA
SCHEMBL5075204 0.88 SIGMAR1 (0.45) SIGMAR1CA12CA9ALDH1A1LMNA
SCHEMBL14010988 0.85 SIGMAR1 (0.43) SIGMAR1ALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080300271-A1 Novel compounds and a novel process for their preparation FAGNOU KEITH 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300271-A1 Novel compounds and a novel process for their preparation NUDT1, NCL, NUCB2 SIGMAR1 487/4885CA12 3325/4885CA1 4059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.